Condition: High Risk Cancer · Pancreatic Cancer · Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
This Phase 1 study will evaluate safety and the immune response to pooled mutant-KRAS peptide vaccine with poly-ICLC adjuvant for patients who have been identified to be at risk of developing pancreatic cancer.
This description comes directly from the study's public registry record.
Colleen Apostol, RN · 410-614-3644 · GIClinicalTrials@jhmi.edu
Always discuss trial participation with your own doctor first.
| Sidney Kimmel Comprehensive Cancer Center | Baltimore, Maryland, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05013216